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The Effects of Tumstatin on 
Vascularity, Airway Inflammation 
and Lung Function in an 
Experimental Sheep Model of 
Chronic Asthma
Joanne Van der Velden1, Louise M. Harkness2,3, Donna M. Barker1, Garry J. Barcham1, 
Cathryn L. Ugalde1, Emmanuel Koumoundouros4, Heidi Bao1, Louise A. Organ1, 
Ana Tokanovic1, Janette K. Burgess2,3,5,* & Kenneth J. Snibson1,*
Tumstatin, a protein fragment of the alpha-3 chain of Collagen IV, is known to be significantly reduced 
in the airways of asthmatics. Further, there is evidence that suggests a link between the relatively 
low level of tumstatin and the induction of angiogenesis and inflammation in allergic airway disease. 
Here, we show that the intra-segmental administration of tumstatin can impede the development of 
vascular remodelling and allergic inflammatory responses that are induced in a segmental challenge 
model of experimental asthma in sheep. In particular, the administration of tumstatin to lung segments 
chronically exposed to house dust mite (HDM) resulted in a significant reduction of airway small blood 
vessels in the diameter range 10+–20 μm compared to controls. In tumstatin treated lung segments 
after HDM challenge, the number of eosinophils was significantly reduced in parenchymal and airway 
wall tissues, as well as in the bronchoalveolar lavage fluid. The expression of VEGF in airway smooth 
muscle was also significantly reduced in tumstatin-treated segments compared to control saline-
treated segments. Allergic lung function responses were not attenuated by tumstatin administration 
in this model. The data are consistent with the concept that tumstatin can act to suppress vascular 
remodelling and inflammation in allergic airway disease.
Angiogenesis is a prominent feature of airway remodelling in asthma. In particular, the airways of people with 
asthma have an increased number and size of blood vessels compared to healthy subjects1–3. The increased num-
ber and/or dimensions of pulmonary vessels in the bronchial mucosa can contribute to lumen narrowing and 
airflow obstruction in asthma4, and may also result in an increase in the trafficking of inflammatory cells and 
mediators to affected airways5. The precise mechanisms that lead to vascular remodelling in asthma are not 
known, although ongoing airway inflammation is thought to be a contributing factor6.
Vascular remodelling is a vital part of normal wound repair and as such is a tightly regulated process of ves-
sel growth and regression. This process is directed by a balance between endogenous pro- and anti-angiogenic 
factors. Pathological angiogenesis is thought to occur when this balance is disrupted. Angiogenic factors such 
as vascular endothelial growth factor (VEGF), angiogenin and monocyte chemotactic protein-1 are increased 
in the bronchoalveolar lavage (BAL) fluid and induced sputum of asthmatics7. In addition to the increased lev-
els of pro-angiogenic factors, the endogenous anti-angiogenic factors are also thought to be altered in the air-
ways of asthmatic patients8,9. Tumstatin, the non-collagenous (NC)1 domain that can be cleaved from the α -3 
chain of Collagen IV, is one such endogenous angiogenic inhibitor. We have recently reported that tumstatin 
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is significantly reduced in the airways of patients with asthma9. Furthermore, administration of tumstatin in a 
murine model of ovalbumin-induced allergic airways disease inhibited angiogenesis, reduced airway responsive-
ness and dampened inflammation, suggesting that tumstatin may be a useful therapeutic intervention in asthma 
and other diseases where aberrant angiogenesis is a prominent feature9.
We have previously shown that chronic challenges with House Dust Mite (HDM) allergen to sheep lung 
segments induces Th-2 driven allergic inflammation which is associated with long-term lung function deterio-
ration and small airway wall remodelling10,11. The small airway remodelling changes in the sheep include: aug-
mented sub-epithelial collagen deposition, increases in airway smooth muscle (ASM) content, and increases in 
airway vascularity and blood vessel density11,12. Our recent study shows that the vascular remodelling changes in 
response to repeated allergen exposure are long-lasting, whereby blood vessel density in the airway walls does not 
revert back to control levels after allergen exposure is ceased for an extended period of time12. The changes to the 
vasculature and ASM in response to allergen, together with the fact that small airway structure and function in 
the sheep lung is comparable to the human lung, make the model relevant for examining the effects of tumstatin 
administration on vascular remodelling in asthma. Hence, the aim of the present study was to investigate whether 
the efficacy of tumstatin at impeding vascular remodelling and reducing airway inflammation reported for the 
mouse model could be verified in a large animal model of allergic asthma.
Materials and Methods
Experimental animals and allergen sensitisation. Female merino-cross ewes (6 months) were immunised sub-
cutaneously with HDM extract (Dermatophagoides pteronyssins; CSL) and atopic sheep selected as described pre-
viously13. All experimental animal procedures and the collection of tissues/cells were carried out in accordance 
with the relevant guidelines and regulations required by the Animal Experimentation Ethics Committee of the 
University of Melbourne which approved this study.
Treatment. A fibre-optic bronchoscope was used for the localised delivery of solutions to individual lung seg-
ments. Three spatially separate lung segments received different treatments as outlined in Fig. 1. The left and right 
caudal lung segments received weekly challenge with HDM (1 mg in 5 mL saline) and twice weekly infusions of 
either tumstatin (150 mg in 5 mL saline) or saline (5 mL) for 24 weeks. The right medial segments received weekly 
challenges of 5 mL saline to act as a control for HDM.
Bronchoalveolar lavage. Bronchoalveolar lavage (BAL) was collected from individual lung segments via 
slow infusion and withdrawal of 10 mL of sterile saline through the working channel of the bronchoscope. The 
samples were collected in week 22 before, and 48 hours after HDM or saline challenges to the various lung seg-
ments (Fig. 1). BAL fluid was collected and stored at − 80 oC until required. Total and differential cell counts were 
determined as previously described14.
Lung function. Peripheral resistance (Rp) of individual lung segments was measured in individual lung seg-
ments of awake, consciously breathing sheep using a wedged-bronchoscope technique and custom-built Airway 
Monitoring System as previously described14. Rp was calculated as mean pressure/flow during tidal breathing 
when pressure had stabilised. Early-phase airway response (EAR) following HDM challenge and airway respon-
siveness to methacholine were assessed as previously described14.
Figure 1. Lung segments used and timeline for procedures and measurements performed on the sheep. 
(a) A sheep lung which has been labelled to show the different lung segments used for the different treatments. 
The left and right distal lung segments received challenges of solubilized house dust mite (HDM) (200 μ g in 
5 mL saline) weekly and treatment with either Tumstatin (150 μ g in 5 mL saline) or saline (5 mL) twice weekly 
respectively. The right medial segment received an equivalent volume of saline to act as a control for HDM.  
(b) Shows the time-line for all treatments and procedures performed on the sheep.
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Lung tissue collection, immunohistochemistry and morphometric analysis. Sheep were euthanised 7 days after 
the final challenge by intravenous barbiturate overdose. Lung segments from all treatment groups were inflated 
with optimal cutting temperature compound (Pro Sci Tech) diluted in saline (1:1). Blood vessels were identified 
on frozen sections of lung tissue immunostained with an antibody against type IV collagen (Dako) as previously 
described12. The density and size of blood vessels within the lamina propria of the airway wall was determined by 
digital image analysis of photographs using Image-Pro Plus (Media Cybernetics, version 4.1.0.0). The area of the 
lamina propria was defined as the area enclosed by the basal surface of the luminal epithelial cells and the luminal 
side of the smooth muscle bundles, using previously described nomenclature15. Two bronchi from the same posi-
tion in the tracheobronchial tree, approximately 1–2 mm diameter and free from branching, were analysed for 
each segment and the results averaged for each sheep. For comparative analysis of blood vessel size, blood vessels 
were sorted into four different size groups based on their diameters. The cohorts of blood vessel diameter ranges 
were 0–10 μ m, 10+–20 μ m, 20+–30 μ m and 30+ μ m. Immuno-stained leukocytes were counted in the airway lam-
ina propria and lung parenchyma at x400 magnification using a calibrated grid of known area in the microscope 
eyepiece. All morphometric analyses were performed by observers who were blinded to the experimental group 
and lung segment.
Immunohistochemistry. Immunohistochemistry was performed on frozen tissue sections as previously 
described12,16. Sections were fixed with 100% cold ethanol for 10 minutes and were simultaneously blocked for 
endogenous peroxidase with 3% H2O2 (Univar, Knoxville, Vic, Australia). Sections were then pre-blocked using 
blocking solution for 30 minutes (1% bovine serum albumin, 5% normal sheep serum in PBS). After washing, 
sections were incubated at RT for 2 hours with the primary antibodies (e.g. anti- VEGF (A-20) rabbit polyclonal, 
1:200; Santa Cruz Biotechnology; mouse anti-human type IV collagen (1:100 Dako, Kingsgrove, Australia)) and 
leukocyte monoclonal antibody markers for CD4, CD8, gamma delta T cell receptor and eosinophils13. After 
washing, sections were incubated for with appropriate secondary antibodies (goat anti-rabbit HRP-conjugated 
secondary antibody, 1:100 Dako; rabbit anti-mouse HRP-conjugated secondary antibody 1:100 Dako) for 1 hour. 
Sections were then washed and a peroxidase-based detection system was used for visualisation. Antibody speci-
ficity was determined by omission of the primary antibodies.
Quantification of VEGF staining. Expression levels of VEGF staining within the airway smooth muscle 
were quantified calculating the intensity of the brown staining within these regions using Fuji (Image J)17. Airway 
smooth muscle bundles were outlined within complete airways and images used for analysis underwent colour 
deconvolution to separate the brown staining from the counterstain. Thresholds for colour (pixel) intensity were 
applied to images to detect the intensity of brown staining (0–166 pixels) and a threshold of 0–255 (total pixels) 
was applied to measure the total area of the region. For each airway, ASM bundles were outlined and area meas-
ured (Threshold 255). The outlined ASM bundles were then measured for VEGF staining (Threshold 160). To 
calculate Mean intensity of VEGF staining in ASM bundles, values at 160 threshold were subtracted from total 
area (threshold 255) i.e. ‘actual mean intensity of ASM (255–160)’.
Statistical analyses. Differences between the segments were assessed using repeated measures (matched) 
one way ANOVA and the Bonferroni test for planned comparisons. Differences between 0 and 48 hour BAL cell 
counts were analysed for each segment using a paired (matched) t-test. Statistical analysis was performed using 
GraphPad Prism for Windows (Version 6.0 GraphPad Software Inc., La Jolla, USA). A P value of < 0.05 was taken 
as significant. Values are reported as mean ± SEM.
Results
The Early Asthmatic Response (EAR). The Early Asthmatic Response (EAR) data shows that admin-
istering HDM alone (without tumstatin) resulted in a 148% increase in resistance in the treated segment at the 
30 minute post-allergen challenge time-point when compared to baseline pre-allergen challenge resistance values 
(Fig. 2a). With tumstatin treatment, the mean change in segmental resistance after HDM allergen exposure was 
152% above baseline values for the 30 minute time-point (Fig. 2a). There were no significant differences in the 
resistance responses between tumstatin- and saline control- treated segments after allergen administration to 
these lung compartments (Fig. 2a). As expected, control lung segments receiving saline challenges alone (without 
HDM) did not exhibit any significant increases in segmental resistance at the 30 minute time-point post saline 
challenge (Fig. 2a). Mean baseline resistances in all differentially treated lung segments at week 0 (before the start 
of the repeated weekly HDM challenge regime) were not significantly different to the respective baseline resist-
ance data assessed at week 23 (Table S1, supplementary data).
Airway responsiveness. Airway responsiveness data from week 24 of the weekly allergen challenge regime 
are shown in Fig. 2b. The data show PC100(MCh) values which indicate the relative mean dose of methacholine 
required to increase peripheral resistance in the nominated segment by 100% over baseline levels after control 
saline challenge. In general, higher PC100(MCh) values indicate that the airways are relatively less responsive to 
methacholine. The analysis demonstrated that there was no significant difference between tumstatin-treated and 
non-tumstatin-treated segments in terms of airway responsiveness to methacholine.
Inflammatory cells. Data for leukocytes recovered from BAL fluids in week 22 is shown in Fig. 3a. The 
results show that the number of macrophages recovered from BAL fluid was significantly increased 48 hours 
after HDM + saline challenge compared with before challenge values. In contrast, with tumstatin treatment, 
the numbers of macrophages recovered 48 hours after HDM challenge were not significantly different from 
‘before HDM challenge’ values (Fig. 3a). The numbers of eosinophils recovered from BAL fluid are significantly 
increased 48 hours after HDM + saline challenge compared with before challenge values. In the segment treated 
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with tumstatin, the numbers of eosinophils recovered 48 hours after HDM challenge was higher than, but not 
significantly different from, ‘before HDM challenge’ values (Fig. 3a). Data for leukocyte densities (CD8, CD4, 
gamma delta T cell receptor, and eosinophils) in the airway walls of the three differentially treated lung segments 
are shown in Fig. 3b. These segments were collected at autopsy 7 days after the last HDM challenge. The data show 
that HDM administration alone induced a significant increase in the density of airway wall eosinophils compared 
with saline vehicle treated segments. In contrast, the density of airway wall eosinophils was significantly reduced 
in HDM + tumstatin treated segments compared with HDM alone treated segments (p < 0.05) (Fig. 3b). Data 
for the relative densities of parenchymal leukocytes in the differentially treated segments shown in Fig. 3c were 
consistent with the airway data. The data show that HDM administration alone induced a significant increase in 
the density of parenchymal eosinophils compared with saline vehicle treated segments. In contrast, the density of 
parenchymal eosinophils was significantly reduced in HDM + tumstatin treated segments compared with HDM 
alone treated segments (p < 0.05). There were no significant differences between the densities of the CD4, CD8, 
and gamma delta T cell receptor lymphocytes in either the airway walls, or in the parenchyma, of the differentially 
treated lung segments.
Airway smooth muscle and lamina propria areas measurements. Airway smooth muscle and lam-
ina propria areas measurements for the three differentially treated lung segments are indicated in Table S1 of the 
supplementary data.
Blood vessel morphometrics. Morphometric data on bronchial blood vessels in the airway lamina pro-
pria of differentially treated lung segments are shown in Fig. 4. Representative sections of airway blood vessels 
stained with ColIV antibody are shown in Fig. 4a,b. The density of blood vessels of all sizes in a unit area of lamina 
propria (vessels/mm2 lamina propria) was lower, but not significantly different, in the HDM + tumstatin treated 
lung segments Fig. 4c. To determine whether tumstatin was having differential effects on different sizes of blood 
vessels represented in histological sections, we sorted blood vessels into four different size groups based on their 
diameters (0–10 μ m, 10+–20 μ m, 20+–30 μ m and 30+ μ m). A comparison between the differentially treated 
lung segments indicated that there was a significant difference in the density of 10+–20 μ m size vessels between 
HDM+ tumstatin and HDM + saline treatments (206 ± 21 v 133 ± 8 vessels/mm2 lamina propria respectively, 
p < 0.05, Fig. 5).
VEGF expression. An analysis of VEGF immunostaining showed that VEGF was expressed predominantly 
in the airway epithelium and airway smooth muscle (Fig. 6a,b). Exposure to HDM, without tumstatin, signifi-
cantly increased the VEGF staining within the ASM bundles compared to the vehicle control (mean intensity 
of VEGF 136.4 ± 7 vs 116.8 ± 5 mean intensity units respectively, p < 0.05). Treatment of the segments with 
HDM + tumstatin prevented the increase in VEGF staining in the ASM (mean intensity of VEGF 120 ± 11 vs 
116.8 ± 5, respectively) (Fig. 6c).
Discussion
In this study we have used our large animal model of experimental chronic asthma12 to explore the effects of 
tumstatin on the disease features that are reflective of those seen in human asthma. Our major findings were that 
intra-lung segmental administration of tumstatin reduced the induction of the development of new blood vessels 
by HDM and attenuated allergic eosinophilic and macrophage responses to HDM challenge. However, the appli-
cation of tumstatin but did not alter lung function indices for either the early-phase asthmatic response or the 
bronchial hyperresponsiveness. These findings suggest that tumstatin may be able to prevent the in vivo induction 
of angiogenesis and the allergic inflammatory response in small airways chronically exposed to allergen.
Figure 2. Airway responsiveness to allergic and non-allergic stimuli at week 24. (a) Percent change in airway 
peripheral airway resistance (Rp) 30 mins post-HDM from the resistance after saline. *p < 0.05. (b) Percent dose 
of methacholine required to increase Rp 100% from the resistance after saline (PC100) 24 hours following HDM 
challenge. Mean + SEM (n = 7 sheep).
www.nature.com/scientificreports/
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Much of the interest in the role that tumstatin plays in asthma stems from a key study reporting that the level 
of tumstatin is decreased 18-fold in the airways of patients with asthma, relative to non-asthmatic subjects9. 
Small animal model data are supportive of a role for tumstatin in asthma in that tumstatin administration to 
mice with induced allergic airways disease suppresses angiogenesis, airway hyperresponsiveness, inflammatory 
cell infiltration, and mucus secretion9. In the current study, morphometric analyses of blood vessels indicate that 
tumstatin treatment of HDM challenged segments resulted in a significantly lower density of small bronchial 
blood vessels compared to equivalent size blood vessels in all other lung segments examined which did not receive 
tumstatin. The process of angiogenesis, the formation of new blood vessels from existing vessels, is a complex 
process that involves the activation and sprouting of the endothelial cells to form the leading tip of the new vessel. 
The environment around the vessel must then be remodelled before the vessel is stabilised. Endothelial cells are 
normally quiescent while they are bound to the capillary BM, this suggests that the initial signals coming from 
the BM inhibit proliferation and facilitate appropriate cell–cell adhesion (which would be seen in the very small 
vessels in our study). Not all new vessels mature to a stable new structure but rather the vast majority begin to 
form and then regress18. Tumstatin targets its actions through inducing apoptosis in the activated endothelial 
cells that are a key component during angiogenesis19,20. In this way it regulates the formation of new blood vessels, 
which are reflected in the 10+–20 μ m blood vessel size cohort in the analysis in this study, but does not alter the 
stability of the preexisting vessels in the airways (reflected in the larger diameter groupings in our study). As such, 
Figure 3. Leukocyte responses in the differentially treated lung segments. Panel (a) shows the numbers of  
leukocytes recovered from BAL fluid at week 22 of the trial both before (0 hr), and 48 hrs after, house dust mite 
(HDM) or saline challenges to the different segments .*p < 0.05 48 hr vs 0 hr. The data in panels (b,c) were 
obtained from frozen sections of the differentially treated lung segments which were immunostained for CD8- 
and CD4-positive lymphocytes, eosinophils, and gamma delta-positive T cell receptor cells. Panel (b) shows 
leukocyte densities in the airway wall of the differenti lung segments. Panel (c) shows leukocyte densities in 
the lung parenchyma of the different lung segments. The results are expressed as means of the differentially 
treatment segments. *p < 0.05 HDM + saline vs vehicle saline, and HDM + tumstatin vs HDM + saline (n = 7 
sheep).
www.nature.com/scientificreports/
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tumstatin would usually play an important regulatory role that assists in the usual maintenance of physiological 
angiogenesis in the airways. The reduction in tumstatin in the airways of people with asthma indicates that this 
physiological balance may have been disrupted, which may explain the increases in blood vessel size and density 
that are present in these airways21–23.
Our results were derived using a recombinant collagen IV NCI fragment introduced into the airways of 
allergic sheep. One potential limitation of the study is that we cannot rule out that our data is the result of a 
non-specific protein fragment effect, as we did not use an inactive recombinant collagen fragment for the con-
trol lung segment. Inactive protein fragments of over 300AA are very difficult to generate for controls, and so 
far, to our knowledge, all collagen fragments that have been examined in in vivo models have been generated to 
investigate an active, rather than an inactive, role in the biological function. To date, studies reporting an active 
biological role of tumstatin have not used an inactive recombinant collagen fragment to illustrate the specificity of 
the response9,19,24. The specificity of the collagen IV NCI fragment has been shown using peptides and scrambled 
controls in in vivo models and support the hypothesis that tumstatin is the biologically active molecule25.
Interestingly, the analyses of lung function data in the differentially treated lung segments, show that tumstatin 
administration does not attenuate lung function indices of EAR and AHR in the sheep model. These results are in 
contrast to the data generated using the mouse allergic airways model where tumstatin improved AHR as well as 
a number indices of allergic inflammation9. This result was surprising as we expected that the tumstatin-induced 
changes to the vascularity and inflammation would improve airway function in the sheep model, as it does in 
mice. Explanations for the contrasting results may be due to factors such as differences in airway structures 
between the two species, as well as the very different protocols associated with measuring lung function in mice 
and sheep. It is noteworthy that the physiological analyses of the current study were conducted on the small 
airways of unanaesthetised spontaneously breathing sheep. Whereas lung function in the mouse study was con-
ducted on whole lungs of anaesthetised mice which were mechanically ventilated9. The major differences in small 
airway structures between the species which may influence function are that small airways of sheep possess 
well-developed bronchial circulations, mast cells and prominent smooth muscle bundles26. These small airway 
features are either absent or poorly developed in the mouse small airway. Interestingly, in our previous publi-
cation, we found that while there were deteriorations in functional indices of EAR or AHR in lung segments of 
sheep chronically exposed to allergen, the changes in small airway function did not directly correlate to increased 
Figure 4. Airway blood vessel density in the differentially treated lung segments. Representative 
photomicrographs of blood vessels stained with Type IV Collagen are shown for (a) HDM + saline, and  
(b) HDM + tumstatin treated lung segments. (c) Shows the density of blood vessels in the airway lamina  
propria immuno-stained with Type IV Collagen (n = 7 sheep).
www.nature.com/scientificreports/
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blood vessel density in response to repeated allergen challenge reported for this sheep model12. Thus, it could be 
reasonably argued that any changes to the vasculature with tumstatin administration that we see in this study are 
unlikely to be prominent enough to produce significant improvements in lung function. Overall, while tumstatin 
had beneficial effects on allergic inflammation and angiogenesis in the sheep model, the lack of improvement in 
pulmonary function after tumstatin administration could indicate a limited usefulness for directly improving 
lung function. It is worth noting that tumstatin may be effective as an add-on therapy for treating asthmatics, 
targeting aspect of remodeling that are not altered by the current therapeutic regime27,28.
While angiogenesis has been studied in the circulation associated with the mouse trachea29 and others have 
shown increased lung vascularity following HDM or ovalbumin exposures30,31 the relevance of these findings 
to human asthma is controversial due to the remodelling of airway bronchial circulation in human asthma as 
opposed to changes in the pulmonary circulation as seen for mice. In the sheep model, as is the case with human 
asthma, the blood vessels of the bronchial circulation in the airway lamina propria are associated with airway 
oedema and are a major entry point for inflammatory cells to migrate into other regions of the airway wall32,33. It 
is possible that the differences in the effectiveness of tumstatin seen in the sheep model presented here compared 
to data from the mouse model are reflective of the altered location of the reduction in angiogenesis, which may 
change the regulation of the influx of inflammatory cells into the airway wall and their impact on AHR.
We found that local tumstatin administration to specific lung segments ameliorated allergic inflammatory 
responses to HDM in these segments. This was evident in the lower numbers of eosinophils present in recovered 
BAL fluid, and lower eosinophil densities observed in parenchymal and airway wall tissues of tumstatin-treated 
lung segments when compared to data derived from comparable segments treated with HDM alone. In this 
respect, our data are consistent with earlier findings which demonstrate that intranasal administration of 
tumstatin in a mouse model of allergic airway disease results in reduced densities of eosinophils and airway 
mucous secreting cells9. While there is very little known with regard to its anti-inflammatory mechanism, the 
Figure 5. Density of different sized blood vessels in the airway lamina propria of differentially treated lung 
segments. Blood vessels in frozen sections were immuno-labelled with a ColIV antibody and then sorted into 
four different size groups based on their diameters. The diameter ranges in the groups were 0–10 μ m, 10+–20 μ m, 
20+–30 μ m and 30+ μ m. *p < 0.05 HDM + tumsatin treatment vs HDM + saline (n = 7 sheep).
www.nature.com/scientificreports/
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administration of tumstatin is known to protect the basement membrane from damage from polymorphonuclear 
cells34. Further, the addition of tumstatin inhibits the accumulation of monocytes and macrophages in a mouse 
model of diabetic neuropathy24. It is of interest that we also see reduced levels of macrophages in BAL fluid 
after HDM challenge and tumstatin treatment. While the above mentioned studies may suggest that tumstatin is 
directly anti-inflammatory, it cannot be ruled out that the amelioration of allergic inflammation is indirectly due 
to tumstatin’s retardation on the growth of new blood vessels which act as a conduit for entry of inflammatory 
cells to airway tissues.
The administration of tumstatin significantly reduced the expression of VEGF protein detected within the 
ASM bundles in the airways. The ASM is a known source of VEGF, releasing it in response to pro-inflammatory 
and pro-fibrotic factors increased in the asthmatic milieu35,36. Whilst the modulation of VEGF levels by tumstatin 
in the ASM has not previously been reported, to our knowledge, it is feasible that tumstatin binds to the integrins 
α vβ 3 or α vβ 5 on the ASM cell surface37,38. Through this interaction it would modulate downstream signalling in 
the ASM cell. It is through binding to this integrin on endothelial cells that tumstatin prevents their receiving the 
survival signal from VEGF and drives the endothelial cells into apoptosis20. These findings suggest that the effects 
of tumstatin in the airways go beyond the immediately recognised effects on endothelial cells. The potential for 
tumstatin to have broader effects on airway remodelling in the asthmatic lung require further investigation.
Overall, this large animal study confirms the important link between the absence of tumstatin and increased 
blood vessel growth and the inflammatory response in asthma. Our findings suggest that application of tumsta-
tin directly to the lung may be able to prevent the in vivo remodelling and inflammation that is associated with 
chronic asthma.
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